CAMBRIDGE, Mass., April 7, 2008 (PRIME NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that new data from several preclinical studies of the company’s novel small molecule drug candidates -- the i.v.-administered Hsp90 inhibitor retaspimycin hydrochloride (also known as IPI-504) and the oral Hedgehog pathway inhibitor IPI-926 -- will be presented during the Annual Meeting of the American Association of Cancer Research (AACR) in San Diego, California, April 12 to 16, 2008.
